ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia
The efficacy of bempedoic acid as an LDL-C-lowering agent has validated ACLY inhibition
as a therapeutic strategy. Positive results of phase 3 patient studies, together with long-term
cardiovascular disease outcome trials, are required to establish ACLY as a major new target
in cardiovascular medicine.
as a therapeutic strategy. Positive results of phase 3 patient studies, together with long-term
cardiovascular disease outcome trials, are required to establish ACLY as a major new target
in cardiovascular medicine.
Summary
The efficacy of bempedoic acid as an LDL-C-lowering agent has validated ACLY inhibition as a therapeutic strategy. Positive results of phase 3 patient studies, together with long-term cardiovascular disease outcome trials, are required to establish ACLY as a major new target in cardiovascular medicine.
Lippincott Williams & Wilkins